p-Hydroxycinnamic acid

Name: p-Hydroxycinnamic acid
Brand: MedChemExpress
SKU: HY-N2391
Rating: 4.5 (1 reviews)

Cat. No.: HY-N2391 Purity: 99.94%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

p-Hydroxycinnamic acid, a common dietary phenol, could inhibit platelet activity, with IC₅₀s of 371 μM, 126 μM for thromboxane B₂ production and lipopolysaccharide-induced prostaglandin E₂ generation, respectively.

For research use only. We do not sell to patients.

p-Hydroxycinnamic acid Chemical Structure

CAS No. : 7400-08-0

Size	Stock	Quantity

Free Sample (0.1 - 0.5 mg)	Apply Now
Solid + Solvent (Highly Recommended)
10 mM * 1 mL in DMSO ready for reconstitution	In-stock	Estimated Time of Arrival: December 31
Solution
10 mM * 1 mL in DMSO	In-stock	Estimated Time of Arrival: December 31
Solid
5 g	In-stock	Estimated Time of Arrival: December 31
10 g	In-stock	Estimated Time of Arrival: December 31
50 g	Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Featured Recommendations

•Related Screening Libraries:

•Related Small Molecules:

•Related Proteins:

View All Prostaglandin Receptor Isoform Specific Products:

View All Isoforms

DP EP FP IP TXA₂/TP TXB₂

Biological Activity
Purity & Documentation
References
Customer Review

Description

IC₅₀ & Target^[1]

TXB₂

371 μM (IC₅₀)

Human Endogenous Metabolite

Cellular Effect

Cell Line	Type	Value	Description	References
A549	IC₅₀	> 10 μM Compound: 6	Cytotoxicity against human A549 cells after 48 hrs by SRB assay Cytotoxicity against human A549 cells after 48 hrs by SRB assay	[PMID: 27700070]
A549	IC₅₀	> 100 μM Compound: 14	Cytotoxicity against human A549 cells after 72 hrs by MTT assay Cytotoxicity against human A549 cells after 72 hrs by MTT assay	[PMID: 21696954]
B16-F10	IC₅₀	> 10 μM Compound: PCA	Cytotoxicity against mouse B16-F10 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against mouse B16-F10 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 33956447]
BT-549	IC₅₀	10 μM Compound: 6	Cytotoxicity against human BT549 cells after 48 hrs by SRB assay Cytotoxicity against human BT549 cells after 48 hrs by SRB assay	[PMID: 27700070]
BV-2	IC₅₀	> 100 μM Compound: 23	Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction based assay Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced NO production after 24 hrs in presence of LPS by Griess reaction based assay	[PMID: 28911817]
BV-2	IC₅₀	> 50 μM Compound: 6	Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay Antineuroinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay	[PMID: 27700070]
HepG2	IC₅₀	> 10 μM Compound: PCA	Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human HepG2 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 33956447]
HT-1080	ED₅₀	> 100 μM Compound: 18	Antiproliferative activity against human HT1080 cells by MTT assay Antiproliferative activity against human HT1080 cells by MTT assay	[PMID: 11277741]
HT-22	EC₅₀	6.4 μM Compound: 29	Neuroprotective activity against glutamate-induced cell death in mouse HT-22 cells assessed as increase in cell viability after 24 hrs by EZ-Cytox assay Neuroprotective activity against glutamate-induced cell death in mouse HT-22 cells assessed as increase in cell viability after 24 hrs by EZ-Cytox assay	[PMID: 32991171]
HT-29	IC₅₀	> 10 μM Compound: PCA	Cytotoxicity against human HT-29 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay Cytotoxicity against human HT-29 cells assessed as cell growth inhibition measured after 72 hrs by MTT assay	[PMID: 33956447]
KB	IC₅₀	> 200 μM Compound: 1f	Antitumor activity against KB cells by MTT assay Antitumor activity against KB cells by MTT assay	[PMID: 17387015]
LoVo	IC₅₀	82 μM Compound: 14	Cytotoxicity against human LoVo cells after 72 hrs by MTT assay Cytotoxicity against human LoVo cells after 72 hrs by MTT assay	[PMID: 21696954]
Oocyte	IC₅₀	9.59 μM Compound: 4-OH-Cin-COOH	Antagonist activity at Gloeobacter violaceus ligand-gated ion channel expressed in Xenopus oocytes assessed as inhibition of MES buffer pH 5.5 -induced currents after 30 secs by voltage clamp technique Antagonist activity at Gloeobacter violaceus ligand-gated ion channel expressed in Xenopus oocytes assessed as inhibition of MES buffer pH 5.5 -induced currents after 30 secs by voltage clamp technique	[PMID: 23682762]
PC-3	IC₅₀	> 100 μM Compound: 14	Cytotoxicity against human PC3 cells after 72 hrs by MTT assay Cytotoxicity against human PC3 cells after 72 hrs by MTT assay	[PMID: 21696954]
Platelet	IC₅₀	74.8 μM Compound: 4-OH-cinnamic acid	Anti-platelet activity in rabbit platelet-rich plasma assessed as inhibition of ADP-induced platelet aggregation incubated for 5 mins at 37 degC by aggregometry Anti-platelet activity in rabbit platelet-rich plasma assessed as inhibition of ADP-induced platelet aggregation incubated for 5 mins at 37 degC by aggregometry	10.1039/C4MD00022F
RAW264.7	IC₅₀	> 50 μM Compound: 11	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production after 24 hrs by Griess method	[PMID: 22079762]
RAW264.7	GI₅₀	4560 μM Compound: 1a	Cytotoxicity against mouse RAW264.7 cells assessed as growth inhibition after 48 hrs by trypan blue assay Cytotoxicity against mouse RAW264.7 cells assessed as growth inhibition after 48 hrs by trypan blue assay	10.1039/C3MD00251A
RAW264.7	IC₅₀	73.4 μM Compound: 11	Antiinflammatory activity in mouse RAW264.7 cells assessed as decrease in LPS-induced NO production after 24 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as decrease in LPS-induced NO production after 24 hrs by Griess assay	[PMID: 25666824]
SK-MEL-2	IC₅₀	> 10 μM Compound: 6	Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB assay Cytotoxicity against human SK-MEL-2 cells after 48 hrs by SRB assay	[PMID: 27700070]
SK-MEL-28	IC₅₀	> 100 μM Compound: 14	Cytotoxicity against human SK-MEL-28 cells after 72 hrs by MTT assay Cytotoxicity against human SK-MEL-28 cells after 72 hrs by MTT assay	[PMID: 21696954]
SK-OV-3	IC₅₀	> 10 μM Compound: 6	Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay Cytotoxicity against human SKOV3 cells after 48 hrs by SRB assay	[PMID: 27700070]
U-373MG ATCC	IC₅₀	> 100 μM Compound: 14	Cytotoxicity against human U373 cells after 72 hrs by MTT assay Cytotoxicity against human U373 cells after 72 hrs by MTT assay	[PMID: 21696954]
U-937	IC₅₀	> 2000 μM Compound: 24, p-coumaric acid	Antiproliferative activity against human U937 cells assessed as incorporation of [3H]-methyl-thymidine after 12 hrs by scintillation counting Antiproliferative activity against human U937 cells assessed as incorporation of [3H]-methyl-thymidine after 12 hrs by scintillation counting	[PMID: 22925447]
U-937	CC₅₀	> 2000 μM Compound: 24, p-coumaric acid	Cytotoxicity against human U937 cells after 48 hrs by trypan blue assay Cytotoxicity against human U937 cells after 48 hrs by trypan blue assay	[PMID: 22925447]

In Vitro

p-Hydroxycinnamic acid (p-Coumaric acid), is a ubiquitous plant metabolite with antioxidant and anti-inflammatory properties. p-Hydroxycinnamic acid (500 μM and 1 mM) reduces ADP-induced platelet aggregation (55?2 (SE 4?01) % and 35?6 (SE 2?35) % relative to basal level, respectively). p-Hydroxycinnamic acid is able to modify platelet function, a shear-inducing device that simulates primary haemostasis. p-Hydroxycinnamic acid interferes also with arachidonic acid cascade, reducing thromboxane B₂ production and lipopolysaccharide-induced prostaglandin E₂ generation (IC₅₀ 371 and 126 μM, respectively)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

164.16

Formula

C₉H₈O₃

CAS No.

7400-08-0

Appearance

Solid

Color

White to off-white

SMILES

O=C(O)/C=C/C1=CC=C(O)C=C1

Structure Classification

Ketones, Aldehydes, Acids

Initial Source

Endogenous metabolite

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	2 years
	-20°C	1 year

Solvent & Solubility

In Vitro:

DMSO : ≥ 100 mg/mL (609.16 mM; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Ethanol : 33.33 mg/mL (203.03 mM; Need ultrasonic)

*"≥" means soluble, but saturation unknown.

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	6.0916 mL	30.4581 mL	60.9162 mL
5 mM	1.2183 mL	6.0916 mL	12.1832 mL
10 mM	0.6092 mL	3.0458 mL	6.0916 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 2 years; -20°C, 1 year. When stored at -80°C, please use it within 2 years. When stored at -20°C, please use it within 1 year.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% EtOH 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (15.23 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% EtOH 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (15.23 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% EtOH 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (15.23 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL EtOH stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.
Protocol 4

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.08 mg/mL (12.67 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 5

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.08 mg/mL (12.67 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 6

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.08 mg/mL (12.67 mM); Clear solution

This protocol yields a clear solution of ≥ 2.08 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (20.8 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.94%

Select Batch:

Data Sheet (270 KB) SDS (393 KB)

COA (244 KB) HNMR (129 KB) RP-HPLC (230 KB)

Handling Instructions (2659 KB)

References

[1]. Luceri C, et al. p-Coumaric acid, a common dietary phenol, inhibits platelet activity in vitro and in vivo. Br J Nutr. 2007 Mar;97(3):458-63. [Content Brief]

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

Ethanol / DMSO	1 mM	6.0916 mL	30.4581 mL	60.9162 mL	152.2904 mL
	5 mM	1.2183 mL	6.0916 mL	12.1832 mL	30.4581 mL
	10 mM	0.6092 mL	3.0458 mL	6.0916 mL	15.2290 mL
	15 mM	0.4061 mL	2.0305 mL	4.0611 mL	10.1527 mL
	20 mM	0.3046 mL	1.5229 mL	3.0458 mL	7.6145 mL
	25 mM	0.2437 mL	1.2183 mL	2.4366 mL	6.0916 mL
	30 mM	0.2031 mL	1.0153 mL	2.0305 mL	5.0763 mL
	40 mM	0.1523 mL	0.7615 mL	1.5229 mL	3.8073 mL
	50 mM	0.1218 mL	0.6092 mL	1.2183 mL	3.0458 mL
	60 mM	0.1015 mL	0.5076 mL	1.0153 mL	2.5382 mL
	80 mM	0.0761 mL	0.3807 mL	0.7615 mL	1.9036 mL
	100 mM	0.0609 mL	0.3046 mL	0.6092 mL	1.5229 mL